Physician profile
Mark E Dubin
NPI 1245202704
$2,242.91
in general payments reported to CMS, 2019-2025
17 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2021: $81.16 · 2022: $377 · 2023: $209 · 2024: $842 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.43 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $290.88 | 2022-2024 | Stelara, Simponi Aria, Remicade |
| E.R. Squibb & Sons, L.L.C. | $203.32 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.45 | 2023-2024 | Entyvio |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Madrigal Pharmaceuticals | $122.82 | 2024 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.07 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $120.84 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $120.66 | 2024 | Iqirvo |
| Medtronic, INC. | $111.92 | 2025 | Interstim |
| Janssen Scientific Affairs, LLC | $110.32 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $104.85 | 2022 | |
| Merck Sharp & Dohme LLC | $101.25 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.56 | 2023 | Jardiance |
| Hologic Sales and Service, LLC | $24.69 | 2024 | Coolseal Generator |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $14.82 | 2024 | |
| Amgen INC. | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.